Related Experiment Video
Updated: Jun 9, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
997
Tofacitinib for child-onset systemic lupus erythematosus
Ling Hou1, Peng Zhou1, Chengguang Zhao1
1Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China.
Frontiers in Immunology
|October 23, 2024
Summary
Tofacitinib may benefit some children with refractory systemic lupus erythematosus (SLE), potentially reducing their need for glucocorticoids. However, not all patients responded to this Janus kinase (JAK) inhibitor treatment.
Area of Science:
- Immunology
- Rheumatology
- Pediatrics
Background:
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with significant morbidity in children (cSLE).
- Current SLE treatments have limitations, including adverse effects and incomplete disease control.
- Tofacitinib, a Janus kinase (JAK) inhibitor, targets the JAK-STAT pathway and may reduce SLE severity.
Purpose of the Study:
- To evaluate the efficacy of tofacitinib in pediatric patients with refractory cSLE.
- To assess the potential for tofacitinib to reduce glucocorticoid dosage in cSLE.
Main Methods:
- Retrospective examination of 9 cSLE patients treated with tofacitinib.
- Analysis of patient case histories, lab results, and treatment regimens.
- Data collected at disease onset, tofacitinib initiation, and up to 24 months post-treatment.
Main Results:
- Four out of 9 female patients with refractory cSLE showed symptom alleviation and reduced prednisone dosage.
- Some patients were able to discontinue other immunosuppressants like cyclosporine A and belimumab.
- Five patients did not experience apparent benefits from tofacitinib treatment.
Conclusions:
- Tofacitinib may offer clinical benefits for select pediatric patients with refractory cSLE.
- It can facilitate a reduction in glucocorticoid therapy for some cSLE patients.
- Tofacitinib shows potential as an adjunctive therapy for specific cSLE cases.
More Related Videos
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
01:27Tumor Immunotherapy
486
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
486
01:20The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K